Table of contents
- Trial overview
- Influenza prevention study in older adults
- COVID-19 vaccine immunology study
- Participants and trial phases
- Main outcomes measured
- What these trials are trying to show
Trial overview
IMELASOMERAN is being studied in clinical trials that look at vaccine effectiveness and immune response.[1][2] The available trials are both Phase 3 studies, which means they involve large groups of people and focus on how well a vaccine strategy works in practice.[1][2]
Both trials are listed as completed, so the study periods have ended.[1][2]
Influenza prevention study in older adults
One trial, NCT05517174, studied prevention of influenza infection in older adults.[1] It compared a high-dose quadrivalent influenza vaccine with a standard-dose quadrivalent influenza vaccine.[1] A quadrivalent vaccine is a vaccine designed to cover four flu strains, and “high-dose” means it contains more vaccine material than the standard dose.[1]
This study was a pragmatic randomized trial, which means people were assigned to groups in a way that aimed to reflect real-world care.[1] The trial enrolled 339,700 participants, making it a very large study.[1]
The main outcome was hospitalization due to influenza or pneumonia, called a composite endpoint because it combines two related serious events into one measure.[1] The study aimed to see whether the high-dose vaccine reduced the risk of these hospitalizations in older adults.[1]
COVID-19 vaccine immunology study
The second trial, 2024-517357-27-00, studied COVID-19 infection and vaccine immunology.[2] This study compared several COVID-19 vaccine products, including BIMERVAX LP.8.1, Spikevax, Comirnaty, Nuvaxovid, and a non-replicating viral vector vaccine.[2]
The main goal was to evaluate immune responses after vaccination with different vaccine formulations.[2] The primary outcome measured the proportion of people who were seropositive and had an antibody level above the target level 6 months after two doses against the prevailing virus variant.[2]
This trial enrolled 4,000 participants.[2] The study was designed to compare how different vaccine products perform in terms of antibody response over time.[2]
Participants and trial phases
The influenza study focused on older adults, a group often included in vaccine research because they may have a higher risk of serious flu-related illness.[1] The COVID-19 study focused on people receiving COVID-19 vaccination, with the goal of comparing immune responses across vaccine products.[2]
Both studies were conducted in Phase 3, which is a late stage of testing before or during broader use of a vaccine.[1][2] Phase 3 trials are important because they help show whether a vaccine strategy works in larger and more varied groups of people.[1][2]
Main outcomes measured
The influenza trial measured hospitalization due to influenza or pneumonia.[1] This outcome matters because it shows whether vaccination can help prevent severe illness that needs hospital care.[1]
The COVID-19 trial measured the proportion of participants with antibody levels above a target level after vaccination.[2] This is a way to check whether the vaccine produces a strong enough immune response in the blood.[2]
What these trials are trying to show
These trials are not simple drug studies; they are vaccine studies that compare different vaccine approaches in specific groups.[1][2] One study asks whether a higher-dose flu vaccine can better protect older adults from serious outcomes.[1] The other asks whether different COVID-19 vaccine products lead to stronger or more durable antibody responses.[2]
Because both studies are completed, their data can help explain how these vaccine strategies performed in large real-world or immunology-focused settings.[1][2]
